MX2024006291A - Anticuerpos monoclonales de adn dirigidos al virus de la influenza. - Google Patents

Anticuerpos monoclonales de adn dirigidos al virus de la influenza.

Info

Publication number
MX2024006291A
MX2024006291A MX2024006291A MX2024006291A MX2024006291A MX 2024006291 A MX2024006291 A MX 2024006291A MX 2024006291 A MX2024006291 A MX 2024006291A MX 2024006291 A MX2024006291 A MX 2024006291A MX 2024006291 A MX2024006291 A MX 2024006291A
Authority
MX
Mexico
Prior art keywords
monoclonal antibodies
influenza virus
antibodies targeting
targeting influenza
dna monoclonal
Prior art date
Application number
MX2024006291A
Other languages
English (en)
Inventor
David B Weiner
Jian Yan
Sarah Elliott
Ami Patel
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2024006291A publication Critical patent/MX2024006291A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe en la presente una composición que incluye una secuencia de ácido nucleico recombinante que codifica un anticuerpo sintético anti-influenza-hemaglutinina; la descripción también proporciona un método para prevenir y/o tratar la influenza en un sujeto utilizando dicha composición y método de generación.
MX2024006291A 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza. MX2024006291A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332381P 2016-05-05 2016-05-05
US201662376162P 2016-08-17 2016-08-17

Publications (1)

Publication Number Publication Date
MX2024006291A true MX2024006291A (es) 2024-08-26

Family

ID=60203613

Family Applications (8)

Application Number Title Priority Date Filing Date
MX2018013521A MX2018013521A (es) 2016-05-05 2017-05-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006292A MX2024006292A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006293A MX2024006293A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006290A MX2024006290A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006289A MX2024006289A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006291A MX2024006291A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024000118A MX2024000118A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006295A MX2024006295A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.

Family Applications Before (5)

Application Number Title Priority Date Filing Date
MX2018013521A MX2018013521A (es) 2016-05-05 2017-05-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006292A MX2024006292A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006293A MX2024006293A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006290A MX2024006290A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006289A MX2024006289A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2024000118A MX2024000118A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024006295A MX2024006295A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.

Country Status (11)

Country Link
US (2) US11851477B2 (es)
EP (1) EP3452504A4 (es)
JP (3) JP7506869B2 (es)
KR (4) KR20230125851A (es)
CN (2) CN118109478A (es)
AU (2) AU2017261305B2 (es)
BR (1) BR112018072708A2 (es)
CA (1) CA3023093A1 (es)
MX (8) MX2018013521A (es)
SG (2) SG11201809783RA (es)
WO (1) WO2017192946A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3452504A4 (en) * 2016-05-05 2020-07-29 The Trustees of The University of Pennsylvania MONOCLONAL DNA ANTIBODIES TARGETING INFLUENZA VIRUS
JP2020500033A (ja) * 2016-11-07 2020-01-09 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー ライム病に対する使用のためのｄｎａ抗体構築物
US20220324948A1 (en) * 2019-07-31 2022-10-13 The Wistar Institute Of Anatomy And Biology Multivalent dna antibody constructs and use thereof
EP4027982A1 (en) * 2019-09-11 2022-07-20 ModernaTX, Inc. Lnp-formulated mrna therapeutics and use thereof for treating human subjects
CA3237090A1 (en) * 2021-11-05 2023-05-11 Dana-Farber Cancer Institute, Inc. Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
WO2025226722A1 (en) * 2024-04-22 2025-10-30 The Wistar Institute Of Anatomy And Biology Dna antibody and immunogen constructs for use in methods of treating and preventing influenza

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
CN100494370C (zh) * 2006-05-26 2009-06-03 神州细胞工程有限公司 一种优化的单克隆抗体
CN101541832B (zh) * 2006-09-07 2014-11-12 克鲁塞尔荷兰公司 能中和流感病毒h5n1的人结合分子及其应用
EP2380976A4 (en) * 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
US8784819B2 (en) * 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
CA2841551C (en) * 2011-07-18 2020-07-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2013114885A1 (en) * 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
BR112015013700A8 (pt) 2012-12-13 2020-02-18 Inovio Pharmaceuticals Inc composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
EP3080159A4 (en) * 2013-12-13 2017-08-02 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
CN107427566B (zh) * 2014-12-01 2021-08-17 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
SG11201808152PA (en) 2016-03-21 2018-10-30 David Weiner Dna antibody constructs and method of using same
EP3452504A4 (en) * 2016-05-05 2020-07-29 The Trustees of The University of Pennsylvania MONOCLONAL DNA ANTIBODIES TARGETING INFLUENZA VIRUS

Also Published As

Publication number Publication date
US20240150442A1 (en) 2024-05-09
MX2024006293A (es) 2024-08-26
KR20230125851A (ko) 2023-08-29
EP3452504A4 (en) 2020-07-29
AU2017261305B2 (en) 2024-06-13
US20190135899A1 (en) 2019-05-09
JP2022116034A (ja) 2022-08-09
KR20240155978A (ko) 2024-10-29
AU2017261305A8 (en) 2019-08-08
US11851477B2 (en) 2023-12-26
KR20190035614A (ko) 2019-04-03
MX2024006290A (es) 2024-08-26
MX2018013521A (es) 2019-06-10
AU2017261305A1 (en) 2018-12-20
WO2017192946A8 (en) 2018-12-27
JP7506869B2 (ja) 2024-06-27
CN110325546A (zh) 2019-10-11
EP3452504A1 (en) 2019-03-13
BR112018072708A2 (pt) 2019-02-19
JP2019521702A (ja) 2019-08-08
MX2024006289A (es) 2024-08-26
MX2024006295A (es) 2024-08-26
SG11201809783RA (en) 2018-12-28
JP2025081330A (ja) 2025-05-27
AU2024203297A1 (en) 2024-06-13
KR20220035288A (ko) 2022-03-21
CN118109478A (zh) 2024-05-31
WO2017192946A1 (en) 2017-11-09
CA3023093A1 (en) 2017-11-09
MX2024000118A (es) 2024-01-22
CN110325546B (zh) 2024-03-19
SG10202011021XA (en) 2020-12-30
KR102375324B1 (ko) 2022-03-18
MX2024006292A (es) 2024-08-26

Similar Documents

Publication Publication Date Title
MX2024006290A (es) Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
MX2018013520A (es) Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control.
MX2017007187A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
CL2019002196A1 (es) Anticuerpos humanos neutralizantes que se unen a hemaglutinina de influenza a. (divisional solicitud 201701610)
CO2017007673A2 (es) Anticuerpos anti-cd47
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
MX366180B (es) Nuevos agentes de union a ha.
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
BR112016022113A2 (pt) anticorpos anti-hemaglutinina do vírus influenza b e métodos de uso
MX382043B (es) Anticuerpo anti-influenza a neutralizantes y usos de los mismos.
MX392761B (es) Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
BR112017022073A2 (pt) método para purificação de proteína
UY38672A (es) Anticuerpo monoclonal que se une específicamente a gitr
MX2015009819A (es) Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
MX2025009846A (es) Composiciones que comprenden moleculas de acido nucleico que codifican anticuerpos sinteticos anti-il-6 y anti-cd126
CL2017001471A1 (es) Nueva estructura de proteína producida por un anticuerpo efectivo usado para inmunización
EA201892523A1 (ru) Днк-моноклональные антитела, нацеленные на вирус гриппа
AR096455A1 (es) Vacuna para la malaria